SCHEMBL2318554

SCHEMBL2318554

NNC(=O)CNc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
ERCC1 P07992 4/20 0.53
ERCC4 Q92889 4/20 0.53
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.51
GAA P10253 2/20 0.51
PKM P14618 1/20 0.51
KDM4E B2RXH2 1/20 0.51
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
HDAC1 Q13547 1/20 0.48
GRK2 P25098 2/20 0.46
ROCK2 O75116 1/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21747434 0.82 ALDH1A1 (0.50) L3MBTL1ERCC1ERCC4ALDH1A1GAA
SCHEMBL1623733 0.81 ERCC1 (0.54) ERCC1ERCC4ALDH1A1LMNAGAA
SCHEMBL1561387 0.81 MAPT (0.70) L3MBTL1ERCC1ERCC4ALDH1A1LMNA
SCHEMBL5443604 0.80 CA12 (0.52) L3MBTL1ALDH1A1LMNAGAAKMT2A
SCHEMBL1627561 0.80 L3MBTL1 (0.65) L3MBTL1ALDH1A1LMNAKDM4EKMT2A
SCHEMBL2321477 0.80 MAPT (0.54) L3MBTL1ALDH1A1LMNAGAAKDM4E
SCHEMBL2319538 0.80 CA12 (0.52) L3MBTL1ALDH1A1LMNAGAAKDM4E
SCHEMBL21834459 0.80 ALDH1A1 (0.51) ERCC1ERCC4ALDH1A1LMNAGAA
SCHEMBL1174341 0.79 PKM (0.56) ERCC1ERCC4ALDH1A1LMNAGAA
SCHEMBL26333385 0.79 ERCC1 (0.53) ERCC1ERCC4ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109331868-B Phenylglycine bifunctional catalyst, and preparation method and application thereof 广东工业大学 2021-03-26 CN claimed
CN-109331868-A A kind of phenylglycine class bifunctional catalysis' agent and its preparation method and application 广东工业大学 2019-02-15 CN claimed
EP-2965755-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES Inoxia Lifesciences GmbH (AT) 2016-01-13 EP claimed
EP-2528595-B1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES INOXIA LIFESCIENCES GMBH (AT) 2015-08-05 EP claimed
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases INOXIA LIFESCIENCES GMBH (AT) 2013-03-14 US claimed
EP-2528595-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES Inoxia Lifesciences GmbH (AT) 2012-12-05 EP claimed
WO-2011091461-A1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) 2011-08-04 WO claimed
CN-116283658-B Hydrazide hydrazone HIF-2 alpha inhibitor and application thereof 浙江大学医学院附属第一医院 2025-04-25 CN disclosed
CN-116283658-A Hydrazide hydrazone HIF-2 alpha inhibitor and application thereof 浙江大学医学院附属第一医院 2023-06-23 CN disclosed
EP-3656847-B1 ADDITIVE COMPOSITION FOR CULTURE MEDIUM, ADDITIVE COMPOUND FOR CULTURE MEDIUM, AND METHOD FOR CULTURE OF CELLS OR TISSUE USING SAME NISSAN CHEMICAL CORP (JP) 2022-08-17 EP disclosed
US-20210353683-A1 ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR NISSAN CHEMICAL CORPORATION (JP) 2021-11-18 US disclosed
US-20210253518-A1 KINASE INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2021-08-19 US disclosed
US-20210253518-A1 KINASE INHIBITOR NISSAN CHEMICAL CORPORATION (JP) 2021-08-19 US disclosed
US-20070135499-A1 Hydrazide compounds AERIE PHARMACEUTICALS, INC. (US) 2007-06-14 US disclosed
WO-2006133216-A2 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 2006-12-14 WO disclosed
EP-0942924-A2 METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS Elan Pharmaceuticals, Inc. (US) 1999-09-22 EP disclosed
US-5935983-A FOR TREATMENT OF RESTENOSIS BAYER AKTIENGESELLSCHAFT (DE) 1999-08-10 US disclosed
WO-1998022494-A9 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS 1998-08-20 WO disclosed
WO-1998022494-A2 METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS ELAN PHARMACEUTICALS, INC. (US) 1998-05-28 WO disclosed
CN-1137380-A Use of phenylcyclohexylcarboxamides BAYER AG (DE) 1996-12-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065962-A1 Compounds For Use In The Treatment Of Diseases SLC10A1, CYP27A1, OAT L3MBTL1 3028/4885ERCC1 3602/4885ERCC4 1912/4885
US-20210253518-A1 KINASE INHIBITOR LATS2, LATS1, MAP3K6 L3MBTL1 674/4885ERCC1 4451/4885ERCC4 4571/4885
US-20210353683-A1 ADDITIVE FOR MEDIUM FOR PROMOTING PRODUCTION OF PARACRINE FACTOR HGF, HDGF, FGF2 L3MBTL1 4707/4885ERCC1 4776/4885ERCC4 4349/4885
US-20070135499-A1 Hydrazide compounds GRK4, GRK2, GRK1 L3MBTL1 4643/4885ERCC1 2781/4885ERCC4 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.